Abstract
Urokinase receptors (uPAR) were initially thought to function simply as a mechanism to concentrate the urokinase / plasmin system toward the cell surface. However, extensive evidence has accumulated that this glycolipidanchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. Mechanisms by which uPAR exercises these functions involve complexing with other membrane proteins for signal transduction. One set of functional partners for uPAR on the cell surface are integrins. Recent studies point to important structural features of uPAR:integrin interactions, indicating uPAR to be a cis-acting integrin ligand. In vivo data reveal altered integrin function and cell migration when uPAR:integrin interactions are impaired. Together these observations support the idea that uPAR:integrin interactions may be a focal point of intervention in pathobiology where integrin function is crucial, such as tumor metastasis.
Current Pharmaceutical Design
Title: Urokinase Receptor and Integrin Interactions
Volume: 9 Issue: 19
Author(s): Matthias C. Kugler, Ying Wei and Harold A. Chapman
Affiliation:
Keywords: urokinase, integrin, adhesion, receptor
Abstract: Urokinase receptors (uPAR) were initially thought to function simply as a mechanism to concentrate the urokinase / plasmin system toward the cell surface. However, extensive evidence has accumulated that this glycolipidanchored receptor also functions in both the adhesive and signaling pathways of many migratory cells. Mechanisms by which uPAR exercises these functions involve complexing with other membrane proteins for signal transduction. One set of functional partners for uPAR on the cell surface are integrins. Recent studies point to important structural features of uPAR:integrin interactions, indicating uPAR to be a cis-acting integrin ligand. In vivo data reveal altered integrin function and cell migration when uPAR:integrin interactions are impaired. Together these observations support the idea that uPAR:integrin interactions may be a focal point of intervention in pathobiology where integrin function is crucial, such as tumor metastasis.
Export Options
About this article
Cite this article as:
Kugler C. Matthias, Wei Ying and Chapman A. Harold, Urokinase Receptor and Integrin Interactions, Current Pharmaceutical Design 2003; 9 (19) . https://dx.doi.org/10.2174/1381612033454658
DOI https://dx.doi.org/10.2174/1381612033454658 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology Copper Chelation Chemistry and its Role in Copper Radiopharmaceuticals
Current Pharmaceutical Design Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Role of Pancreatic β-Cell Death and Cell Death-Associated Inflammation in Diabetes
Current Molecular Medicine Systemic Therapeutic Gene Delivery for Cancer: Crafting Paris Arrow
Current Gene Therapy Polysialyltransferase: A New Target in Metastatic Cancer
Current Cancer Drug Targets Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Current Signal Transduction Therapy TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Reviews on Recent Clinical Trials The Development of Future Research Strategies from Reviewing Antiemetic Trials for Chemotherapy Induced Emesis
Reviews on Recent Clinical Trials Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences The Ubiquitous Choline Transporter SLC44A1
Central Nervous System Agents in Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Interplay between Epigenetics & Cancer Metabolism
Current Pharmaceutical Design Evolution and Structure of API5 and Its Roles in Anti-Apoptosis
Protein & Peptide Letters Strong Anti-tumorous Potential of Nardostachys jatamansi Rhizome Extract on Glioblastoma and In Silico Analysis of its Molecular Drug Targets
Current Cancer Drug Targets miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective
Anti-Cancer Agents in Medicinal Chemistry Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Current Pharmaceutical Biotechnology